长效肽设计 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
== Biochemistry == Androgens like testosterone are responsible for penis enlargement and elongation during puberty. Penis size is positively correlated with increasing testosterone levels during puberty. But after puberty, administration of testosterone does not affect penis size, and androgen deficiency in adult men only results in a small decrease in size. Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) are also involved in penis size, with deficiency (such as that observed in growth hormone deficiency or Laron syndrome) at critical developmental stages having the potential to result in micropenis.
==== Hypogonadism ==== An absolute deficiency in androgen production due to primary or secondary hypogonadism can cause gynecomastia. Primary hypogonadism results when there is damage to the testes (due to radiation, chemotherapy, infections, trauma, etc.), leading to impaired androgen production. It can also be caused by chromosomal abnormality seen in Klinefelter syndrome, which is associated with gynecomastia in about 80% of cases. Secondary hypogonadism results when there is damage to the hypothalamus or pituitary (due to radiation, chemotherapy, infection, trauma, etc.), and similarly leads to impaired androgen production. The net effect is reduced androgen production while serum estrogen levels (from peripheral aromatization of androgens) remain unaffected. The lack of androgen-mediated inhibition of breast tissue proliferation, combined with relative estrogen excess, results in gynecomastia.
== Fascial dynamics == Deep fascia is less extensible than superficial fascia. It is essentially avascular, but is richly innervated with sensory receptors that report the presence of pain (nociceptors); change in movement (proprioceptors); change in pressure and vibration (mechanoreceptors); change in the chemical milieu (chemoreceptors); and fluctuation in temperature (thermoreceptors). Deep fascia is able to respond to sensory input by contracting; by relaxing; or by adding, reducing, or changing its composition through the process of fascial remodeling. Fascia may be able to contract due to the activity of myofibroblasts which may play a role in wound healing. The deep fascia can also relax. By monitoring changes in muscular tension, joint position, rate of movement, pressure, and vibration, mechanoreceptors in the deep fascia are capable of initiating relaxation. Deep fascia can relax rapidly in response to sudden muscular overload or rapid movements. Golgi tendon organs operate as a feedback mechanism by causing myofascial relaxation before muscle force becomes so great that tendons might be torn. Pacinian corpuscles sense changes in pressure and vibration to monitor the rate of acceleration of movement. They will initiate a sudden relaxatory response if movement happens too fast. Deep fascia can also relax slowly as some mechanoreceptors respond to changes over longer timescales. Unlike the Golgi tendon organs, Golgi receptors report joint position independent of muscle contraction. This helps the body to know where the bones are at any given moment.
Nelumbo nucifera contains some thermal-stable proteins that might be useful in protein bioengineering processes. The proteins are characterized by seed longevity used for cell protection and repair under stress. There are also several indications that compounds of N. nucifera are used in drug fabrication in human health research for multiple purposes. Lotus leaves possess hydrophobic characteristics, attributed to a waxy coat that prevents water from adhering to the surface. This attribute has influenced the conception of the "lotus effect" in biomimicry and engineering, guiding the design of materials that resist water and remain self-cleaning. Researchers at the National University of Singapore have utilized the water-repelling structure as inspiration for developing eAir, an aero-elastic sensor capable of detecting subtle pressure changes or other environmental stimuli.
== Etymology == in 1842 the English paleontologist Sir Richard Owen coined the term "dinosaur", using it to refer to the "distinct tribe or sub-order of Saurian Reptiles" that were then being recognized in England and around the world. The term is derived from Ancient Greek δεινός (deinos) 'terrible, potent or fearfully great' and σαῦρος (sauros) 'lizard or reptile'. Though the taxonomic name has often been interpreted as a reference to dinosaurs' teeth, claws, and other fearsome characteristics, Owen intended it also to evoke their size and majesty.
Sources: en.wikipedia.org
Salutaridinol is a modified benzyltetrahydroisoquinoline alkaloid with the formula C19H23NO4. It is produced in the secondary metabolism of the opium poppy Papaver somniferum (Papaveraceae) as an intermediate in the biosynthetic pathway that generates morphine. As an isoquinoline alkaloid, it is fundamentally derived from tyrosine as part of the shikimate pathway of secondary metabolism. Salutaridinol is a product of the enzyme salutaridine: NADPH 7-oxidoreductase and the substrate for the enzyme salutaridinol 7-O-acetyltransferase, which are two of the four enzymes in the morphine biosynthesis pathway that generates morphine from (R)-reticuline. Salutaridinol's unique position adjacent to two of the four enzymes in the morphine biosynthesis pathway gives it an important role in enzymatic, genetic, and synthetic biology studies of morphine biosynthesis. Salutaridinol levels are indicative of the flux through the morphine biosynthesis pathway and the efficacy of both salutaridine: NADPH 7-oxidoreductase and salutaridinol 7-O-acetyltransferase.
These effects are referred to as epigenetic and involve the higher order structure of DNA, non-sequence specific DNA binding proteins and chemical modification of DNA. In general epigenetic effects alter the accessibility of DNA to proteins and so modulate transcription.
=== Condensate microenvironment === The condensate microenvironment refers to the distinct internal physical and chemical conditions within biomolecular condensates that influence molecular behavior and biochemical activity. These environments can differ markedly from the surrounding cellular milieu in terms of material property, pH, and chemical property. Rather than acting solely as passive concentration hubs, condensates modulate their internal milieu to promote selective partitioning, regulate reaction kinetics, and enable context-specific biological functions. Experimental studies have revealed several mechanisms by which condensate microenvironments operate. The material properties of condensates have been linked to condensate composition and functions. Nucleolar condensates have been shown to maintain internal pH gradients that influence RNA processing and protein composition. Other studies have demonstrated that different nuclear condensates exhibit distinct solvent characteristics, shaping the partitioning behavior of small molecules and biochemical cofactors. Further direct evidence comes from experiments using synthetic tools to manipulate condensate material properties. One study introduced a genetically encoded peptide, killswitch, that selectively arrests condensate dynamics without disrupting their scaffolds, enabling controlled perturbation of condensate material property in live cells. This intervention altered the protein composition of transcriptional condensates and impaired their biological activity.
Produced by Debra Bauer, directed by Chris Rawlence, made by Hayer Rawlence 18 November Superpowers? with Ray Hyman, about the international group of sceptics Committee for Skeptical Inquiry, who dispute topics such as UFOs; Paul Kurtz; Charles Honorton; Stanton T. Friedman and Philip J. Klass; psychologist Sue Blackmore; the Mars effect by French psychologist Michel Gauquelin, supported by psychologist Hans Eysenck; sociologist Marcello Truzzi; the Flixborough explosion in June 1974 and Lesley Castleton née Brennan from Weelsby Street, Cleethorpes, who had a premonition six hours before it took place, telling her friends at lunchtime before it had occurred; Russell Targ; physicist Robert G. Jahn and David Marks. Narrated by David Neal, executive produced by Jerome Kuehl, produced/directed by Adrian Pennink, made by Open Media 25 November Sex, Lies and Toupee Tape. with Neil Innes. Explores the medical conditions that result in baldness, as well as the dermatological and hormonal physiology of normal pattern balding in aging men (and women). Neil composes and performs songs to illustrate the topic, as well as acting as the guinea pig for numerous ancient and mythical remedies. The psychology and sociology of baldness is also examined, featuring wigs, toupees, ointments and surgical intervention. The programme visits the Bald Headed Men of America annual convention in Morehead North Carolina. It was written, produced and directed by Chris Haws and was an InCA production.
== History and etymology == Proline was first isolated in 1900 by Richard Willstätter who obtained the amino acid while studying N-methylproline, and synthesized proline by the reaction of sodium salt of diethyl malonate with 1,3-dibromopropane. The next year, Emil Fischer isolated proline from casein and the decomposition products of γ-phthalimido-propylmalonic ester, and published the synthesis of proline from phthalimide propylmalonic ester. The name proline comes from pyrrolidine, one of its constituents.
Sources: en.wikipedia.org
Clomipramine may interact with monoamine oxidase inhibitors (MAOIs) such as isocarboxazid, moclobemide, phenelzine, selegiline, and tranylcypromine. These combinations are generally avoided due to the severe risk of adverse reactions. The medication also interacts with antiarrhythmic agents because tricyclic antidepressants (TCAs) can significantly alter cardiac conduction. A specific pharmacokinetic interaction exists with quinidine; since clomipramine is metabolized by the enzyme CYP2D6 in vivo, quinidine can impede this process and raise drug levels. Similarly, diuretics pose a secondary risk; by potentially inducing hypokalaemia (low blood potassium), they increase the likelihood of QT interval prolongation and the life-threatening heart rhythm known as torsades de pointes. Furthermore, clomipramine reacts with selective serotonin reuptake inhibitors (SSRIs) through two distinct mechanisms. First, there is a risk of additive serotonergic effects that can lead to serotonin syndrome. Second, a pharmacokinetic interaction occurs with SSRIs that inhibit CYP2D6—specifically fluoxetine and paroxetine—which can lead to toxic levels of clomipramine in the bloodstream. This risk of serotonin toxicity or serotonin syndrome extends to other serotonergic agents, including triptans, other tricyclic antidepressants, and tramadol. Fluvoxamine increases the serotonergic effects of clomipramine and, likewise, clomipramine increases fluvoxamine levels.
=== Small-cell lung cancer === Around 15% of all lung cancers (also called carcinomas) are small-cell lung cancers, and around 85% are non-small-cell lung cancers. Small-cell lung carcinoma (SCLC) has long been divided into two clinicopathological stages, termed limited stage (LS) and extensive stage (ES). The stage is generally determined by the presence or absence of metastases, whether or not the tumor appears limited to the thorax, and whether or not the entire tumor burden within the chest can feasibly be encompassed within a single radiotherapy portal. In general, if the tumor is confined to one lung and the lymph nodes close to that lung, the cancer is said to be LS. If cancer has spread beyond that, it is said to be ES. Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for the highest mortality rates among both men and women. When associated with the lung, SCLC is sometimes called "oat cell carcinoma" due to the flat cell shape and scanty cytoplasm. Small cell mesothelioma – an extremely rare subtype of lung cancer – can be mistaken for small cell lung cancer. Small-cell carcinoma is most often more rapidly and widely metastatic than non-small-cell lung carcinoma (and hence staged differently). There is usually early involvement of the hilar and mediastinal lymph nodes. The mechanisms of its metastatic progression are not well understood.
Fe3+ + 3 H2O → Fe(OH)3↓ + 3 H+ The iron(III) ion ("ferric iron") can also oxidize pyrite: FeS2(s) + 14 Fe3+ + 8 H2O → 15 Fe2+ + 2 SO2−4 + 16 H+ When iron(III) oxidation of pyrite occurs, the process can become rapid. pH values below zero have been measured in ARD produced by this process. ARD can also produce sulfuric acid at a slower rate, so that the acid neutralizing capacity (ANC) of the aquifer can neutralize the produced acid. In such cases, the total dissolved solids (TDS) concentration of the water can be increased from the dissolution of minerals from the acid-neutralization reaction with the minerals. Sulfuric acid is used as a defense by certain marine species, for example, the phaeophyte alga Desmarestia munda (order Desmarestiales) concentrates sulfuric acid in cell vacuoles.
Primary algae are those with "primary chloroplasts", i.e. chloroplasts with two membranes, evolved through a single symbiogenetic event with an endosymbiont β-cyanobacterium as early as 1.6 Gya during the Mesoproterozoic. These algae are mainly grouped in the clade Archaeplastida (meaning "ancient plastid"), which includes the major groups Viridiplantae (green algae sensu lato and all land plants) and Rhodophyta (red algae) as well as the minor group Glaucophyta (grey algae). The chloroplasts of red algae have chlorophyll a and c (often) and phycobilins, with extra-plastid starch storage; green algae chloroplasts have chlorophyll a and b without phycobilins, with intra-plastid starch storage; while grey algae chloroplasts have chlorophylls similar to red algae, but with a peptidoglycan outer layer. Land plants (embryophytes) are pigmented similarly to green algae and likely evolved from the freshwater green algae clade Streptophyta, which is sister taxon to Chlorophyta (green algae sensu stricto) and the basal clade Prasinodermophyta. There is also a minor group of amoeboid protists with primary plastids evolved via different origin and at a much later date than archaeplastid chloroplasts. The four species of the euglyphid amoebae genus Paulinella, have cyanobionts (known as cyanelles) that perform photosynthesis, likely originated from the endosymbiosis of a α-cyanobacterium (probably an ancestral member of Chroococcales), about 90–140 Mya during the Cretaceous.
The modern method of embalming involves the injection of various chemical solutions into the arterial network of the body to primarily disinfect and slow the decomposition process. William Harvey, the 17th century English physician who was the first to detail the system of blood circulation, made his discoveries by injecting colored solutions into corpses. The Scottish surgeon William Hunter was the first to apply these methods to the art of embalming as part of mortuary practice. He wrote a widely read report on the appropriate methods for arterial and cavity embalming in order to preserve bodies for burial. His brother, John Hunter, applied these methods and advertised his embalming services to the general public from the mid-18th century. One of his more notorious clients was dentist Martin Van Butchell. When his wife Mary died on 14 January 1775, he had her embalmed as an attraction to draw more customers. Hunter injected the body with preservatives and color additives that gave a glow to the corpse's cheeks, replaced her eyes with glass eyes, and dressed her in a fine lace dress. The body was embedded in a layer of plaster of Paris in a glass-topped coffin. Butchell exhibited the body in the window of his home and many Londoners came to see it; however, Butchell drew criticism for the display. A rumor, possibly started by Butchell himself, claimed that his wife's marriage certificate had specified that her husband would only have control over her estate after her death for as long as her body was kept unburied.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.